We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
101
Corbus Pharmaceuticals
CRBP
$166M
$66K 0.01%
13,239
-15,512
-54% -$109K
IVA
102
Inventiva
IVA
$1.06B
$48K 0.01%
13,236
-2,343
-15% -$11K
PHXM
103
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2K ﹤0.01%
+302
New +$2.99K
ACET icon
104
Adicet Bio
ACET
$85.2M
– –
-8,951
Closed -$2.09M
ALDX icon
105
Aldeyra Therapeutics
ALDX
$92.9M
– –
-375,000
Closed -$1.5M
ALNY icon
106
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-291,300
Closed -$42.5M
ALNY icon
107
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-39,900
Closed -$5.82M
AMGN icon
108
CALL
Amgen
AMGN
$208B
– –
-100,000
Closed -$24.3M
AMLX icon
109
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-246,554
Closed -$6.15M
APLS
110
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-123,200
Closed -$5.57M
APLS
111
DELISTED
Apellis Pharmaceuticals
APLS
– –
-41,900
Closed -$1.89M
LONA
112
CALL
LeonaBio Inc
LONA
$66.3M
– –
-78,420
Closed -$2.39M
LONA
113
PUT
LeonaBio Inc
LONA
$66.3M
– –
-19,950
Closed -$609K
AXSM icon
114
CALL
Axsome Therapeutics
AXSM
$11.2B
– –
-350,000
Closed -$13.4M
BBIO icon
115
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-200,000
Closed -$1.82M
BMRN icon
116
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-106,700
Closed -$8.84M
BMRN icon
117
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-60,000
Closed -$4.97M
BPMC
118
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-64,000
Closed -$3.23M
CASI
119
DELISTED
CASI Pharmaceuticals
CASI
– –
-132,014
Closed -$378K
CLDX icon
120
CALL
Celldex Therapeutics
CLDX
$2.99B
– –
-506,500
Closed -$13.7M
CLDX icon
121
PUT
Celldex Therapeutics
CLDX
$2.99B
– –
-616,700
Closed -$16.6M
CLNN icon
122
Clene
CLNN
$64M
– –
-3,500
Closed -$232K
BGMS
123
Bio Green Med Solution Inc
BGMS
$4.91M
– –
-29
Closed -$113K
DBVT
124
DBV Technologies
DBVT
$799M
– –
-31,694
Closed -$1.4M
DRUG
125
Bright Minds Biosciences
DRUG
$719M
– –
-21,192
Closed -$86K
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.